ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1159

Uveitis in Psoriatic Arthritis: Study of 406 Patients in a Single University Center

Ana De Vicente-Delmás1, Lara Sánchez-Bilbao2, Vanesa Calvo Río3, David Martínez-López2, Alba Herrero-Morant4, Eva Galíndez-Agirregoikoa5, Nuria Barroso-García6, Natalia Palmou-Fontana2, Miguel Ángel González-Gay7 and Ricardo Blanco8, 1Hospital General Santa María del Puerto, Cádiz, Spain, 2Hospital Universitario Marqués de Valdecilla, Santander, Spain, 3Valdecilla Hospital, Santander, Spain, 4Hospital Universitario Marqués de Valdecilla, Ontinyent, Spain, 5Basurto University Hospital, Bilbao, Spain, 6Hospital Universitario Puerta del Mar, Cádiz, Spain, Cádiz, Spain, 7Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, 8Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain

Meeting: ACR Convergence 2022

Keywords: Biologicals, Disease-Modifying Antirheumatic Drugs (Dmards), Psoriatic arthritis, spondyloarthritis, Tumor necrosis factor (TNF)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: Spondyloarthritis Including PsA – Basic Science Poster

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: The manifestations of uveitis are well-established in Axial Spondyloarthritis (ax-SpA), but not in Psoriatic Arthritis (PsA). We aimed to assess, in a large unselected series of PsA: a) the frequency and clinical features of uveitis; b) its association with PsA activity, the impact of disease and functional disability, and, c) its relationship with the biologic treatment. Besides, a literature review was performed.

Methods: Cross-sectional study of PsA patients from a single referral hospital. PsA was classified according to the CASPAR criteria, and uveitis was diagnosed by experienced ophthalmologists.

Results: We studied 406 patients with PsA (46.3±12.3 years). Uveitis was observed in 20 (4.9%). Uveitis was acute in all cases, anterior (80%), unilateral (80%) and recurrent (50%). Patients with uveitis had a higher prevalence of HLA-B27 (45% vs 7.5%, p< 0.0001), sacroiliitis on MRI (25% vs 8.3% p=0.027), ocular surface pathology (10% vs 0.8%, p=0.021), and median PsAID (5.9 [2.1-6.8] vs 1.25[0.0-3.0], p=0.001) and BASFI (4 [1.6-5] vs 1.0 [0.0-3.5], p=0.01).The general features of patients and the comparison between patients with and without uveitis is shown in the Table.The incidence (episodes/100 patients-year) of uveitis before versus after biologic treatment decreased with anti-TNFα monoclonal antibodies (56.3 vs 9.4) and increased with etanercept (ETN) (6.03 vs 24.2) and secukinumab (SECU) (0 vs 50) (Figure).

Conclusion: The prevalence of uveitis in patients with PsA was about 5%. The pattern was similar to that observed in ax-SpA. Uveitis was associated with a greater impact of the disease and greater functional disability. The uveitis rate decreased with anti-TNFα monoclonal antibodies and increased with ETN and SECU.

Supporting image 1

Table. General features of 406 patients with Psoriatic Arthritis. Comparison between patients with and without uveitis.

Supporting image 2

Figure. Uveitis incidence rate before and after biological therapy.


Disclosures: A. De Vicente-Delmás, None; L. Sánchez-Bilbao, Eli Lilly; V. Calvo Río, AbbVie/Abbott, Eli Lilly, Merck/MSD, UCB; D. Martínez-López, None; A. Herrero-Morant, None; E. Galíndez-Agirregoikoa, None; N. Barroso-García, None; N. Palmou-Fontana, None; M. González-Gay, AbbVie/Abbott, Merck/MSD, Janssen, Roche, AbbVie/Abbott, Roche, Sanofi, Eli Lilly, Celgene, Sobi, Merck/MSD; R. Blanco, Eli Lilly, Pfizer, Roche, Janssen, MSD, AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Galapagos, Novartis, Sanofi.

To cite this abstract in AMA style:

De Vicente-Delmás A, Sánchez-Bilbao L, Calvo Río V, Martínez-López D, Herrero-Morant A, Galíndez-Agirregoikoa E, Barroso-García N, Palmou-Fontana N, González-Gay M, Blanco R. Uveitis in Psoriatic Arthritis: Study of 406 Patients in a Single University Center [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/uveitis-in-psoriatic-arthritis-study-of-406-patients-in-a-single-university-center/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/uveitis-in-psoriatic-arthritis-study-of-406-patients-in-a-single-university-center/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology